Jazz Pharma Downgraded By Vetr

Jazz Pharmaceuticals PLC JAZZ shares have traded up 45 percent in the last six months, and the Vetr community has downgraded the stock from 3.5 stars to 3 stars.

The stock is down about seven handles since its underwhelming first-quarter earnings report on May 9.

See how crowdsourced ratings can help predict the market?

Vetr members have given Jazz Pharma a Hold rating and $156.97 price target. This price target is lower than the $182.93 price target from Wall Street analysts. The company opened Tuesday around $149.

Of all Vetr raters, about 43 percent believe traders and investors should buy Jazz Pharma stock.

For Vetr’s full analysis of Jazz Pharma, go here.